ClinicalTrials.gg
CompletedNCT07843732Updated Sep 28, 2026

Baricitinib for Central Centrifugal Cicatricial Alopecia in Adults of African Descent

A Phase 2 interventional study of Baricitinib in Central Centrifugal Cicatricial Alopecia, sponsored by Raven Clinical Research. Completed at 4 sites in United States. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Raven Clinical Research · Phase 2, Interventional, and Treatment

How we know

Updated Sep 28, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.

Enrollment
142nd of 204
27 · median 40
Started
2024
with 19 others
Phase 2
48 of 217
7 open now
Registered
182nd of 217
by date

Among the 217 studies in Alopecia with a site in United States, this one is the 142nd largest by enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2024, is one of 48 in phase 2, and was the 182nd registered.

Alopecia

512 studies on the registry are indexed under Alopecia; 127 are open to participants now.

Browse Alopecia studies →

Open to participants now

43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 217 studies in Alopecia with a site in United States, or all of them as a file.
02

Study summary

This study evaluated the safety and efficacy of baricitinib 4 mg daily in adults of African descent with biopsy-proven central centrifugal cicatricial alopecia, a scarring alopecia for which no FDA-approved treatment exists. Participants received open-label baricitinib for 52 weeks at four sites in the United States. Scalp hair loss was assessed by the Investigator Global Assessment at baseline and by the Investigator Re-Assessment Score at each post-baseline visit, with patient-reported quality of life and scalp symptom measures collected in parallel.

Read the detailed description

Single-arm, open-label, Phase 2 study conducted in three periods: a screening period of approximately 4 weeks, a 52-week treatment period from Day 1 through Day 365, and a post-treatment follow-up period of approximately 4 weeks. Participants attended a screening visit, eight in-office visits and five safety follow-up telephone contacts. Investigational product was dispensed at Visits 2, 4, 6, 8 and 10 and collected at each subsequent visit for accountability. Efficacy was assessed by direct clinical examination supported by standardized clinical photography. Safety assessments included vital signs, physical assessment, laboratory analysis, the Columbia-Suicide Severity Rating Scale and adverse event collection at every contact. Twenty-seven participants received at least one dose and 17 completed the Day 365 visit.

03

Conditions studied

  • Central Centrifugal Cicatricial Alopecia

Browse trials for

Keywords

  • CCCA
  • scarring alopecia
  • cicatricial alopecia
  • JAK inhibitor
  • baricitinib
  • skin of color
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 to 75 years of age at the time of .
  2. Of African descent.
  3. -proven central centrifugal cicatricial alopecia with no other cause of hair loss.
  4. Agrees to use no other medication to treat central centrifugal cicatricial alopecia for the duration of the study.
  5. Women of must use highly effective during the intervention period and for 28 days after the last dose, and must have negative pregnancy tests at screening and at baseline.
  6. In otherwise good general health by medical history, physical examination and laboratory testing.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or breastfeeding.
  2. Any other form of alopecia, or any concomitant scalp or skin condition that would interfere with evaluation of study medication.
  3. Active systemic disease that may cause hair loss.
  4. Intralesional , oral JAK inhibitors, or any other treatment for central centrifugal cicatricial alopecia within 4 weeks of baseline.
  5. Systemic therapy within 8 weeks of baseline, or other non-biologic systemic agents within 4 weeks of baseline.
  6. Participation in another interventional study within 4 weeks, or previous treatment with baricitinib.
  7. Active tuberculosis, inadequately treated latent tuberculosis, , , or infection.
  8. Current or recent serious infection, or a history of recurrent eczema herpeticum.
  9. Screening laboratory values outside protocol-specified hematologic, hepatic or renal limits.
  10. Renal impairment.
  11. History of venous thromboembolism or high risk for venous thromboembolism.
  12. Myocardial infarction, unstable ischemic heart disease, stroke, or Class III or IV heart failure within 12 weeks of screening.
  13. History of lymphoproliferative disease, active , or malignancy in remission for less than 5 years.
  14. to any component of study drug.
  15. within 12 weeks of baseline or anticipated during the study.
  16. Unable or unwilling to comply with study procedures for the duration of the study.
  17. Investigator site personnel directly affiliated with this study, or their immediate family.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Baricitinib 4 mg daily

    Participants received baricitinib 2 mg orally twice daily, for a total daily dose of 4 mg, for 52 weeks.

    Drug: Baricitinib

Interventions

  • Oral tablet, 2 mg twice daily for a total daily dose of 4 mg, administered for 52 weeks.

    Also known as: Olumiant, LY3009104

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Investigator Global Assessment Score at Month 12

    The Investigator Global Assessment is a single-item observer-rated scale of scalp hair loss scored from 0 to 4, where 0 is none and 4 is very severe. One score is recorded per participant per timepoint. Change from baseline is the Month 12 score minus the baseline score, reported in units on a scale. A negative value indicates improvement.

    Time frame: Baseline and Month 12

Secondary outcomes

  1. Investigator Re-Assessment Score

    The Investigator Re-Assessment is a single-item observer-rated scale of scalp hair loss relative to baseline, scored from -3 to 3, where -3 is severely worse, 0 is stable with no change and 3 is greatly improved. One score is recorded per participant per timepoint and is reported in units on a scale. Higher scores indicate greater improvement.

    Time frame: Months 1, 3, 6, 9 and 12

  2. Change from Baseline in Investigator Global Assessment Score at Months 1, 3, 6 and 9

    The Investigator Global Assessment is a single-item observer-rated scale of scalp hair loss scored from 0 to 4, where 0 is none and 4 is very severe. Change from baseline is the score at each timepoint minus the baseline score, reported in units on a scale. A negative value indicates improvement.

    Time frame: Baseline and Months 1, 3, 6 and 9

  3. Change from Baseline in Psychological Quality of Life Total Score

    Participant-completed questionnaire of five items on the effect of central centrifugal cicatricial alopecia on hair styling, daily activities, work and personal relationships. Each item is scored 0 not at all to 3 very much, and the five items are summed to a total score of 0 to 15, reported in units on a scale. Change from baseline is the score at each timepoint minus the baseline score. A negative value indicates improvement.

    Time frame: Baseline and Months 1, 3, 6, 9 and 12

  4. Change from Baseline in Patient Subjective Measurements Total Score

    Participant-rated scalp symptom questionnaire of five items: itching, burning or stinging, tenderness, soreness and sharp pain. Each item is rated 0 not at all to 10 most severe imaginable, and the five items are summed to a total score of 0 to 50, reported in units on a scale. Change from baseline is the score at each timepoint minus the baseline score. A negative value indicates improvement.

    Time frame: Baseline and Months 1, 3, 6, 9 and 12

  5. Number of Participants With at Least One Dermatoscopic Feature of Central Centrifugal Cicatricial Alopecia Present

    Participants are counted once at each timepoint if any of the following is present on dermatoscopic examination: peripilar grey or white halo, perifollicular scaling, honeycomb pattern, erythema, increased interfollicular distance, broken hairs, pinpoint white dots, or interfollicular hyperpigmented patches. Reported as number of participants.

    Time frame: Months 1, 3, 6, 9 and 12

07

Study locations

4 sites
  • Site 02
    Marriottsville, Maryland 21104, United States
  • Site 03
    Fairfax, Virginia 22033, United States
  • Site 01
    McLean, Virginia 22102, United States
  • Site 04
    Burlington, Wisconsin 53105, United States
08

References and documents

Individual participant data

Plan to share: Yes

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2024 to primary completion in Apr 2026, 18 months.

Of 42 phase 2 interventional studies under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's 18 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 10, 2024
First posted
Sep 28, 2026
StartActual
Oct 22, 2024
Primary completionActual
Apr 28, 2026
CompletionActual
Apr 28, 2026
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07843732
Lead sponsor
Raven Clinical Research
Responsible party
Sponsor
First posted
Sep 28, 2026
Start date
Oct 22, 2024
Primary completion
Apr 28, 2026
Completion
Apr 28, 2026
Last update
Sep 28, 2026

Study contacts

Chesahna Kindred, MD, MBA, FAAD
principal investigator · Raven Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Baricitinib

Start the discussion